SCHEMBL26640288

SCHEMBL26640288

CC(C)(C)OC(=O)N1CCc2cnc(Nc3cccc(CS(C)(=O)=O)c3)nc2C1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.55
▸ CDK5 Q00535 1/20 0.46
▸ CDK5R1 Q15078 1/20 0.46
▸ MAPK1 P28482 5/20 0.44
▸ GPR119 Q8TDV5 1/20 0.43
▸ KDR P35968 4/20 0.43
▸ PKMYT1 Q99640 1/20 0.43
▸ PDGFRB P09619 1/20 0.43
▸ JAK2 O60674 2/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ PTK2 Q05397 2/20 0.42
▸ DDB1 Q16531 1/20 0.42
▸ CRBN Q96SW2 1/20 0.42
▸ FYN P06241 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ NR1H2 P55055 1/20 0.41
▸ MET P08581 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30648780 1.00 MAPT (0.55) MAPTCDK5CDK5R1MAPK1GPR119
SCHEMBL26640906 0.91 MAPT (0.62) MAPTMAPK1GPR119KDRPDGFRB
SCHEMBL26640680 0.88 MAPT (0.55) MAPTCDK5CDK5R1MAPK1KDR
SCHEMBL30648697 0.88 MAPT (0.55) MAPTCDK5CDK5R1MAPK1KDR
SCHEMBL26640195 0.88 MAPT (0.56) MAPTCDK5CDK5R1MAPK1GPR119
SCHEMBL30648720 0.88 MAPT (0.56) MAPTCDK5CDK5R1MAPK1GPR119
SCHEMBL26640978 0.88 CDK2 (0.53) MAPTCDK5CDK5R1MAPK1KDR
SCHEMBL30648854 0.88 CDK2 (0.53) MAPTCDK5CDK5R1MAPK1KDR
SCHEMBL26640350 0.87 MAPT (0.54) MAPTMAPK1GPR119KDRPDGFRB
SCHEMBL30648637 0.87 MAPT (0.53) MAPTCDK5CDK5R1MAPK1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 MAPT 3283/4885CDK5 389/4885CDK5R1 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback